The GLP-1 receptor agonist reduces both calorie intake through appetite suppression and slightly increases energy expenditure, creating a caloric deficit that drives weight loss
The exciting beyond obesity frontier for GLP-1 drugs is their potential to treat conditions where inflammation, or other non-obesity factors, are the primary cause
The powder is FSSAI-approved
Welocme the domestic and foreign friends come to our factory for visiting.
Patients who push through the first four to eight weeks of treatment, with appropriate management of their symptoms, typically find that side effects improve substantially even as the dose continues to increase
Reduces Oxidative Stress Free radicals from pollution, UV rays, and stress contribute to inflammation and skin damage